AU2001249120A1 - Hiv immune adjuvant therapy - Google Patents

Hiv immune adjuvant therapy

Info

Publication number
AU2001249120A1
AU2001249120A1 AU2001249120A AU4912001A AU2001249120A1 AU 2001249120 A1 AU2001249120 A1 AU 2001249120A1 AU 2001249120 A AU2001249120 A AU 2001249120A AU 4912001 A AU4912001 A AU 4912001A AU 2001249120 A1 AU2001249120 A1 AU 2001249120A1
Authority
AU
Australia
Prior art keywords
hiv
alfa
pegylated interferon
patient
interferon alfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249120A
Other languages
English (en)
Inventor
Mark A. Laughlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2001249120A1 publication Critical patent/AU2001249120A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2001249120A 2000-03-09 2001-03-08 Hiv immune adjuvant therapy Abandoned AU2001249120A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18833800P 2000-03-09 2000-03-09
US60188338 2000-03-09
PCT/US2001/007453 WO2001066132A2 (fr) 2000-03-09 2001-03-08 Traitement adjuvant favorisant une reponse immunitaire au vih

Publications (1)

Publication Number Publication Date
AU2001249120A1 true AU2001249120A1 (en) 2001-09-17

Family

ID=22692745

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249120A Abandoned AU2001249120A1 (en) 2000-03-09 2001-03-08 Hiv immune adjuvant therapy

Country Status (14)

Country Link
US (1) US20020004584A1 (fr)
EP (1) EP1263457A2 (fr)
JP (1) JP2003525907A (fr)
CN (1) CN1416351A (fr)
AU (1) AU2001249120A1 (fr)
BR (1) BR0108997A (fr)
CA (1) CA2402024A1 (fr)
HK (1) HK1047406A1 (fr)
HU (1) HUP0300354A3 (fr)
MX (1) MXPA02008756A (fr)
NO (1) NO20024255L (fr)
NZ (1) NZ520055A (fr)
WO (1) WO2001066132A2 (fr)
ZA (1) ZA200205846B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9849372B2 (en) 2012-09-28 2017-12-26 Sony Interactive Entertainment Inc. Method and apparatus for improving efficiency without increasing latency in emulation of a legacy application title
CN1944644B (zh) * 2006-06-20 2011-11-16 浙江大学 HIV-1gp120与人γ干扰素融合蛋白的制备方法
NZ789041A (en) 2010-06-03 2023-09-29 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US9694276B2 (en) 2012-06-29 2017-07-04 Sony Interactive Entertainment Inc. Pre-loading translated code in cloud based emulated applications
US9925468B2 (en) 2012-06-29 2018-03-27 Sony Interactive Entertainment Inc. Suspending state of cloud-based legacy applications
EP2877598A1 (fr) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutations associées à la résistance à des inhibiteurs de la tyrosine kinase de bruton (btk)
US10406429B2 (en) 2012-08-29 2019-09-10 Sony Interactive Entertainment, LLC User-based mini-game generation and distribution
US9707476B2 (en) 2012-09-28 2017-07-18 Sony Interactive Entertainment Inc. Method for creating a mini-game
US11013993B2 (en) 2012-09-28 2021-05-25 Sony Interactive Entertainment Inc. Pre-loading translated code in cloud based emulated applications
EP2914263A4 (fr) 2012-11-02 2016-04-27 Pharmacyclics Inc Thérapie adjuvante par inhibiteur de kinase de la famille tec
WO2015143400A1 (fr) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Mutations de phospholipase c gamma 2 et associées aux résistances

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
MX9307733A (es) * 1992-12-23 1994-06-30 Schering Corp Restauracion de la funcion inmunologica en pacientes asintomaticos de vih-positivo.
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
PT730470E (pt) * 1993-11-10 2002-08-30 Enzon Inc Conjugados melhorados de interferao-polimero
US5780220A (en) * 1994-05-19 1998-07-14 Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting HIV replication
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US20020182179A1 (en) * 1999-03-02 2002-12-05 Laughlin Mark A HIV Therapy
AR029337A1 (es) * 1999-03-02 2003-06-25 Schering Corp Uso de interferon alfa pegilado para la preparacion de un medicamento para la terapia contra el hiv

Also Published As

Publication number Publication date
MXPA02008756A (es) 2003-02-24
CA2402024A1 (fr) 2001-09-13
HUP0300354A2 (hu) 2003-06-28
HUP0300354A3 (en) 2005-07-28
ZA200205846B (en) 2003-10-22
US20020004584A1 (en) 2002-01-10
BR0108997A (pt) 2003-06-03
NZ520055A (en) 2004-06-25
WO2001066132A3 (fr) 2002-01-24
EP1263457A2 (fr) 2002-12-11
NO20024255D0 (no) 2002-09-06
HK1047406A1 (zh) 2003-02-21
JP2003525907A (ja) 2003-09-02
CN1416351A (zh) 2003-05-07
NO20024255L (no) 2002-09-06
WO2001066132A2 (fr) 2001-09-13

Similar Documents

Publication Publication Date Title
EP1175224B1 (fr) Pharmacotherapie anti-vih utilisant une combinaison d'un peg-interferon-alpha et d'un antagoniste ccr5
KR100309059B1 (ko) 인터페론을함유하는치료학적배합물
JP2004511513A (ja) リバビリン−ＰＥＧ化インターフェロンαＨＣＶ併用治療
US20070248572A1 (en) Method for treating diseases with omega interferon
US7247631B2 (en) Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
US20020004584A1 (en) HIV immune adjuvant therapy
WO2000051631A2 (fr) Traitement du vih
US20020182179A1 (en) HIV Therapy
ES2239953T3 (es) Tratamiento del carcinoma de celulas renales.
JP2001288110A6 (ja) 腎細胞ガン処置
WO2008021487A1 (fr) Méthode de traitement combiné utilisant l'interféron-tau
US8217014B2 (en) Pharmaceutical composition for treatment of blood clotting disorder
TWI271196B (en) CML therapy